(S)-3-amino-2-chloro-4-N-(1-methoxymethyl-3-methoxypropyl)-6-methyl-pyridin-4-amine | 197803-44-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (S)-3-amino-2-chloro-4-N-(1-methoxymethyl-3-methoxypropyl)-6-methyl-pyridin-4-amine
• 英文别名: 2-chloro-4-N-[(2S)-1,4-dimethoxybutan-2-yl]-6-methylpyridine-3,4-diamine
• CAS: 197803-44-4
• 化学式: C₁₂H₂₀ClN₃O₂
• 分子量: 273.763
• InChiKey: LIBMRSQEMOANHL-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  69.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-Chloro-6-methyl-3-nitro-N-(1-methoxymethyl-3-methoxypropyl)pyridin-4-amine 在 溶剂黄146 作用下， 以 盐酸 、 甲醇 、 乙酸乙酯 为溶剂， 生成 (S)-3-amino-2-chloro-4-N-(1-methoxymethyl-3-methoxypropyl)-6-methyl-pyridin-4-amine
  参考文献：
  名称：

  Arylamino fused pyrimidines

  摘要：

  Corticotropin releasing factor (CRF) 拮抗剂的化学式I或化学式II：##STR1## 及其在治疗焦虑、抑郁和其他精神和神经系统疾病中的应用。

  公开号：

  US06107300A1

文献信息

• Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders
  申请人：——

  公开号：US20010025042A1

  公开（公告）日：2001-09-27

  Corticotropin releasing factor (CRF) antagonists of Formula (I): 1 and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

  Corticotropin releasing factor (CRF)拮抗剂的公式（I）：1及其用于治疗精神障碍和神经系统疾病、焦虑相关障碍、创伤后应激障碍、上行性麻痹和进食障碍，以及治疗哺乳动物中与心理病理紊乱和压力相关的免疫、心血管或心脏相关疾病和结肠过敏性反应。
• Arylamino fused pyridines
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：US06448261B1

  公开（公告）日：2002-09-10

  Corticotropin releasing factor (CRF) antagonists of formula I; and their use in treating anxiety, depression, and other psychiatric and neurological disorders.

  Corticotropin releasing factor (CRF)拮抗剂I式; 及其在治疗焦虑、抑郁和其他精神和神经系统疾病中的应用。
• Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
  申请人：DuPont Pharmaceuticals Company

  公开号：US06245769B1

  公开（公告）日：2001-06-12

  Corticotropin releasing factor (CRF) antagonists of Formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

  Corticotropin releasing factor (CRF) Formula (I)的拮抗剂及其在治疗精神障碍和神经系统疾病、焦虑相关疾病、创伤后应激障碍、上行性麻痹、进食障碍以及治疗哺乳动物免疫、心血管或心脏相关疾病和与心理病理障碍和压力相关的结肠过敏性疾病中的应用。
• HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1012151B1

  公开（公告）日：2002-08-07
• US6107300A
  申请人：——

  公开号：US6107300A

  公开（公告）日：2000-08-22